The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation study of azacitidine in combination with temozolomide in patients with soft tissue sarcomas.
I. Matushansky
No relevant relationships to disclose
K. E. Coakley
No relevant relationships to disclose
T. S. Uldrick
No relevant relationships to disclose
R. N. Taub
No relevant relationships to disclose